Anthea Lau
Overview
Explore the profile of Anthea Lau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
210
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khan S, LeBlanc R, Gyger M, White D, Kaufman J, Jazubowiak A, et al.
Leuk Lymphoma
. 2021 Jan;
62(7):1721-1729.
PMID: 33509009
We report results of a phase-1 study evaluating the safety and anti-cancer activity of the small molecule insulin-like growth factor-1 receptor (IGF-1R) inhibitor, linsitinib combined with bortezomib, and dexamethasone in...
2.
Misra S, Lee G, Korzets Y, Wang L, Lau A, Koch C, et al.
Breast Cancer Res Treat
. 2020 Jul;
183(2):391-401.
PMID: 32651754
Purpose: Although regional nodal irradiation (RNI) improves outcomes in breast cancer (BC) patients, it is associated with increased toxicity. Therefore, controversy still exists surrounding its indications. The purpose of this...
3.
Chen C, Cao Y, Trudel S, Reece D, Kukreti V, Tiedemann R, et al.
Leuk Lymphoma
. 2020 Jun;
61(8):1860-1868.
PMID: 32476520
Lenalidomide is a backbone agent in the treatment of multiple myeloma, but dose adjustment is required for those with renal impairment (RI). We evaluated the pharmacokinetics (PK) and safety of...
4.
Chen C, Paul H, Snitzler S, Kakar S, Le L, Wei E, et al.
Leuk Lymphoma
. 2018 Oct;
60(4):980-989.
PMID: 30277089
Lenalidomide has anti-tumor activity in CLL but can be complicated by tumor lysis syndrome (TLS) and tumor flare (TF). In our previous study using low-dose lenalidomide in treatment-naive CLL, TLS...
5.
Raman S, Yau V, Pineda S, Le L, Lau A, Bezjak A, et al.
Clin Lung Cancer
. 2018 Jul;
19(5):e803-e810.
PMID: 30007498
Introduction: Patients with ultracentral lung tumors, whose planning target volume directly contacts or overlaps the proximal bronchial tree, trachea, esophagus, pulmonary vein, or pulmonary artery, may be at higher risk...
6.
Chen C, Paul H, Le L, Wei E, Snitzler S, Wang T, et al.
Leuk Lymphoma
. 2018 Jun;
60(1):92-100.
PMID: 29916761
AKT plays a centralized role in tumor proliferation and survival and is aberrantly activated in chronic lymphocytic leukemia (CLL). In this phase 2 trial, 30 relapsed/refractory CLL patients were treated...
7.
Yau V, Lindsay P, Le L, Lau A, Wong O, Glick D, et al.
Int J Radiat Oncol Biol Phys
. 2018 Apr;
101(3):574-580.
PMID: 29680259
Purpose: To explore and quantify the relationship between esophageal dose and toxicity in the setting of lung stereotactic body radiation therapy (SBRT). Methods And Materials: This analysis was conducted on...
8.
Bartoszko J, Panzarella T, McNamara C, Lau A, Schimmer A, Schuh A, et al.
Clin Lymphoma Myeloma Leuk
. 2017 Jul;
17(11):774-781.
PMID: 28711573
Background: We sought to describe the distribution and impact of comorbidities on outcomes in patients with myelofibrosis, a disease characterized by aberrant bone marrow function with eventual fibrosis. Comorbidities were...
9.
Martin P, Shiau C, Pasic M, Tsao M, Kamel-Reid S, Lin S, et al.
Br J Cancer
. 2016 Feb;
114(6):616-22.
PMID: 26889973
Background: We examined clinical outcomes in a population-based cohort of EGFR mutant advanced NSCLC patients, exploring the potential role of factors including tumour EGFR mutation fraction and cellularity in predicting...
10.
Bartoszko J, Panzarella T, Lau A, Schimmer A, Schuh A, Shanavas M, et al.
Clin Lymphoma Myeloma Leuk
. 2015 Nov;
15(11):e151-6.
PMID: 26566925
Background: There are 2 widely used criteria for red blood cell (RBC) transfusion dependence in persons with myeloproliferative neoplasm (MPN)-associated myelofibrosis: (1) the International Working Group-Myelofibrosis Research and Therapy (IWG-MRT)...